Veraplex

Veraplex is a progestogenic agent used in systemic therapy.

Indications Veraplex

It is used in the presence of an inoperable hormone-sensitive cancer of the endometrium, and also for breast cancer during menopause, accompanied by metastases.

Release form

The release of the drug substance is made in tablets with a volume of 0.1 g (10 pieces inside a cell package and 10 such packages in a box), as well as 0.5 g (10 pieces inside a package, 3 packages in a box).

Pharmacodynamics

Medroxyprogesterone Acetate is an artificial progestogen with antiandrogenic, antiestrogenic and antigonadotropic activity. The drug inhibits the release of pituitary gonadotropins, thereby preventing the process of ovulation in women who remain in the child-bearing age.

When used by men, medroxyprogesterone acetate slows down the activity of interstitial cells, which reduces the formation of testosterone.

Introduction in large portions causes an antitumor effect in case of malignant hormone-sensitive tumors. It is due to the activity shown in relation to the endings of steroid hormones, as well as the pituitary-gonadal axis.

Pharmacokinetics

An orally taken substance is suctioned at high speed. The most effective drug level is observed within 2-7 hours from the time of use. With the introduction of 0.5 g of medroxyprogesterone acetate, the Cmax values after 78 hours reach 78.7-121 ng / ml. Indicators of the substance increase in the case of increasing the dosage.

The drug with its metabolic products passes inside the kidneys, NS and placenta. About 90-95% of medroxyprogesterone acetate undergoes intraplasma protein synthesis.

The excretion of the drug occurs along with urine and bile, in the form of complex compounds.

Dosing and administration

Take medication should be with food.

For the treatment of endometrial cancer, it is required to take 0.2-0.5 g of medicine per day.

In the case of breast cancer treatment, it is necessary to use 0.5 g of drugs a day. If required, the portion can be increased (with the permission of the doctor). This parameter depends on the patient's response to therapy and the stage of the pathology. Information on the safety of taking medroxyprogesterone in daily portions in excess of 1.2 g is not available for treatment of breast carcinoma.

Therapy should be carried out until a clinical result is obtained.

The effect of medroxyprogesterone acetate treatment in some cases develops only after 2-2.5 months of use of the drug.

As the disease progresses, therapy with the use of Veraplex is canceled.

[2]

Use Veraplex during pregnancy

Do not assign Veraplex breastfeeding or pregnant women.

Contraindications

Main contraindications:

• the presence of intolerance in relation to medroxyprogesterone acetate or other elements of the drug;
• HF with severe severity;
• elevated BP, as well as thromboembolic diseases, having a recurrent form;
• disorders of the liver activity in severe cases: for example, hepatitis or intrahepatic cholestasis (or if the patient had previously had these disorders, but the values of the hepatic function did not stabilize), Dubin-Johnson syndrome, as well as hepatic tumors and Rotor syndrome;
• disorders arising or aggravated during therapy with the use of sex hormones (for example, intrahepatic cholestasis, otosclerosis, painful, severely pronounced itching, porphyria, and herpes developing in pregnant women);
• having an unknown origin of bleeding from the vagina;
• unexplained bleeding from the urethra;
• structural changes in the mammary glands of indeterminate genesis.

Side effects Veraplex

Receiving a therapeutic agent can cause some side effects:

• allergy symptoms: anaphylaxis with anaphylactic signs, as well as angioedema;
• CNS damage: fatigue, irritability or drowsiness, dizziness, depression, insomnia and headaches;
• disorders affecting the subcutaneous layer and the epidermis: itching, alopecia, acne, urticaria, and hirsutism;
• disorders of reproductive activity: prolonged anovulation, menstruation cycle disorders (amenorrhea or the sudden appearance of bleeding), as well as cervical discharge processes;
• breast problems: galactorrhea or tenderness;
• disorders of the digestive function: nausea or intrahepatic cholestasis;
• disorders in the work of the cardiovascular system: an increase in blood pressure, tachycardia, heart failure, heartbeat, and in addition thrombophlebitis with thromboembolism;
• lesions of the visual organs: retinal thrombosis and impaired vision;
• metabolic disorders: adrenergic-like symptoms (hyperhidrosis, hand tremors and cramps that affect the gastrocnemius muscles at night) and decreased glucose tolerance;
• changes in laboratory test readings: increased platelet count with leukocytes;
• disorders of the gastrointestinal tract: vomiting, changes in appetite, diarrhea, dyspeptic symptoms and nausea;
• other signs: weight gain, moon face, flushing, hyperthermia, and retention of fluid inside the body.

[1]

Overdose

Intoxication may cause vomiting, pain in the abdominal area and nausea.

To eliminate these disorders, symptomatic procedures are prescribed.

[3]

Interactions with other drugs

Combined use with aminoglutethimide significantly increases the bioavailability of medroxyprogesterone acetate.

Administration of Medroxyprogesterone Acetate can affect laboratory results: plasma progesterone values, estrogen levels (women), gonadotropins, testosterone (men), the level of pregnandiol within the urine, check for metirapone and glucose tolerance.

[4], [5]

Storage conditions

Veraplex is required to keep in a dry place, closed from the penetration of children. Temperature marks are in the range of 15-25 ° С.

[6]

Shelf life

Veraplex is allowed to apply for a 5-year period from the date of manufacture of the drug.

Application for children

The medicine is not used in pediatrics.

Analogs

Analogues of the drug are the substances Depo-Provera, Cyclotal, Provera with Megestron, and besides Medroxyprogesterone-LENS, Farlutal and MPA.

[7]